These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22646221)

  • 1. Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.
    Patnaik S; Zheng W; Choi JH; Motabar O; Southall N; Westbroek W; Lea WA; Velayati A; Goldin E; Sidransky E; Leister W; Marugan JJ
    J Med Chem; 2012 Jun; 55(12):5734-48. PubMed ID: 22646221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.
    Jung O; Patnaik S; Marugan J; Sidransky E; Westbroek W
    Expert Rev Proteomics; 2016 May; 13(5):471-9. PubMed ID: 27098312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional screening of pharmacological chaperones via restoration of enzyme activity upon denaturation.
    Shanmuganathan M; Britz-McKibbin P
    Biochemistry; 2012 Oct; 51(39):7651-3. PubMed ID: 22970758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
    Marugan JJ; Zheng W; Motabar O; Southall N; Goldin E; Westbroek W; Stubblefield BK; Sidransky E; Aungst RA; Lea WA; Simeonov A; Leister W; Austin CP
    J Med Chem; 2011 Feb; 54(4):1033-58. PubMed ID: 21250698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.
    Zheng W; Padia J; Urban DJ; Jadhav A; Goker-Alpan O; Simeonov A; Goldin E; Auld D; LaMarca ME; Inglese J; Austin CP; Sidransky E
    Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13192-7. PubMed ID: 17670938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
    Trapero A; Llebaria A
    Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase.
    Goldin E; Zheng W; Motabar O; Southall N; Choi JH; Marugan J; Austin CP; Sidransky E
    PLoS One; 2012; 7(1):e29861. PubMed ID: 22272254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease?
    Trapero A; Llebaria A
    Future Med Chem; 2014 Jun; 6(9):975-8. PubMed ID: 25068980
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.
    Serra-Vinardell J; Díaz L; Gutiérrez-de Terán H; Sánchez-Ollé G; Bujons J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Grinberg D; Vilageliu L; Casas J
    Int J Biochem Cell Biol; 2014 Sep; 54():245-54. PubMed ID: 25084554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of Gaucher disease.
    Joosten A; Decroocq C; de Sousa J; Schneider JP; Etamé E; Bodlenner A; Butters TD; Compain P
    Chembiochem; 2014 Jan; 15(2):309-19. PubMed ID: 24375964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Acid β-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease.
    Parmeggiani C; Catarzi S; Matassini C; D'Adamio G; Morrone A; Goti A; Paoli P; Cardona F
    Chembiochem; 2015 Sep; 16(14):2054-64. PubMed ID: 26376302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease.
    Egido-Gabás M; Canals D; Casas J; Llebaria A; Delgado A
    ChemMedChem; 2007 Jul; 2(7):992-4. PubMed ID: 17479993
    [No Abstract]   [Full Text] [Related]  

  • 14. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
    Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
    Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
    J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.
    Yang C; Rahimpour S; Lu J; Pacak K; Ikejiri B; Brady RO; Zhuang Z
    Proc Natl Acad Sci U S A; 2013 Jan; 110(3):966-71. PubMed ID: 23277556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease.
    Trapero A; González-Bulnes P; Butters TD; Llebaria A
    J Med Chem; 2012 May; 55(9):4479-88. PubMed ID: 22512696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.
    Yu Z; Sawkar AR; Whalen LJ; Wong CH; Kelly JW
    J Med Chem; 2007 Jan; 50(1):94-100. PubMed ID: 17201413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel compounds that reverse the disease phenotype in Type 2 Gaucher disease patient-derived cells.
    Childers W; Fan R; Martinez R; Colussi DJ; Melenski E; Liu Y; Gordon J; Abou-Gharbia M; Jacobson MA
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126806. PubMed ID: 31757667
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.